Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;38(5):1214-1223.
doi: 10.1007/s11606-022-07786-w. Epub 2022 Oct 11.

Prevalence of Substance Use Disorders in Sickle Cell Disease Compared to Other Chronic Conditions: a Population-Based Study of Black American Adults

Charles R Jonassaint  1   2   3 , Julia O'Brien  4 , Emily Nardo  5 , Robert Feldman  5 , Michael Stanton  6 , Laura DeCastro  7 , Kaleab Z Abebe  5
Affiliations

Prevalence of Substance Use Disorders in Sickle Cell Disease Compared to Other Chronic Conditions: a Population-Based Study of Black American Adults

Charles R Jonassaint et al. J Gen Intern Med. 2023 Apr.

Abstract

Background: Sickle cell disease (SCD) is a heritable chronic health condition characterized by pain symptoms throughout the life course that are routinely treated with opioids.

Objective: This study examined differences in substance use disorders in Black American adults with SCD compared to those with other chronic conditions or with no chronic conditions.

Design: Data from a population-representative sample of Black Americans with SCD, other chronic conditions, and no chronic conditions were obtained from the National Survey of American Life (NSAL) database. Diagnosis of substance use disorder was determined by structured clinical interview. Hierarchical models controlling for covariates (demographics, socioeconomic status, self-rated health, and mood disorders) compared odds of diagnosis between the three groups.

Participants: The sample included 4238 African-American and Black Caribbean participants from the NSAL study who were 18 years of age or older.

Main measures: Measures included age, sex, income, education, marital status, employment, possession of health insurance, health conditions, and substance use disorders diagnosed by structured clinical interview.

Key results: Controlling for age, sex, and socioeconomic status, there were no differences in odds of a drug use disorder when comparing individuals with SCD to Black adults with other chronic conditions (OR = 1.12; p = 0.804) or no chronic condition (OR = 2.09; p = 0.102). SCD was, however, associated with greater odds of alcohol use disorders when compared to the groups with other chronic conditions (OR = 2.15; p = 0.01) and no chronic conditions (OR = 5.11; p < 0.001). This effect was not better accounted for by socioeconomic status, marital status, self-rated physical health, or the presence of a mood disorder.

Conclusions: SCD was not a risk factor for drug use disorders. Further data will be needed to understand the factors contributing to increased risk of alcohol use disorders in SCD and the role uncontrolled pain symptoms may have in driving substance use.

Keywords: alcohol use disorder; chronic disease; drug use disorder; sickle cell; substance use disorder.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to report.

References

    1. Brousseau DC, Panepinto JA, Nimmer M, Hoffmann RG. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010;85(1):77-8. 10.1002/ajh.21570. - PubMed
    1. Tanabe P, Spratling R, Smith D, Grissom P, Hulihan M. CE: Understanding the complications of sickle cell disease. Am J Nurs. 2019;119(6):26-35. 10.1097/01.NAJ.0000559779.40570.2c. - PMC - PubMed
    1. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701. 10.1182/bloodadvances.2020001851. - PMC - PubMed
    1. Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf. 2018;27(5):479-486. 10.1002/pds.4291. - PMC - PubMed
    1. Ballas SK. Opioids and sickle cell disease: from opium to the opioid epidemic. J Clin Med. 2021;10(3):438. 10.3390/jcm10030438. - PMC - PubMed